Cell line · CVCL_1584
Papers36
1 to 20 of 36
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Humanized antibody-drug conjugates for Somatostatin receptor 2 (SSTR2)-positive tumor treatment. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A first-in-class EGFR-directed KRAS G12V selective inhibitor. | Cancer Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. | Cell Rep Methods | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. | Elife | 2024 | Its Methods give the RRID and name the line | PubMed | |
| DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. | Cell Chem Biol | 2020 | Its Methods give the RRID and name the line | PubMed | |
| From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. | J Cell Biochem | 2020 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. | Cell | 2018 | Cellosaurus cites it | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed | |
| A Landscape of Pharmacogenomic Interactions in Cancer. | Cell | 2016 | Cellosaurus cites it | PubMed | |
| TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. | Genome Med | 2015 | Cellosaurus cites it | PubMed | |
| Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. | Cancer Genet | 2015 | Cellosaurus cites it | PubMed | |
| A resource for cell line authentication, annotation and quality control. | Nature | 2015 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1584/papers